Moberg Pharma AB (publ)
Nasdaq Stockholm · LEI 549300XFXK7DVGDRP410· Fiscal year 2025
Staff cost per employee
Not disclosed
Employees
Not disclosed
Quick read
- Operating loss of $2.7M in 2025.
Last 3 years
Revenue
Operating income
See the share price on Google Finance ↗
Investor metrics
2025
- Operating margin
- -201.8%
- Net margin
- -201.2%
- ROE
- -4.1%
- Debt-to-equity
- 2.6%
- Equity ratio
- 97.5%